Tag: Penumbra

New Late Breaking Data Show Patients Treated with Penumbra’s Computer Assisted Vacuum Thrombectomy Technology for Pulmonary Embolism Experience Shorter Hospital Stays and Fewer Complications Compared to Other Treatment Options

Data presented for the first time this week at Vascular Interventional Advances (VIVA) 2024 Conference Findings reinforce the clinical, health economic and cost benefits of computer assisted vacuum thrombectomy to patients and the overall health system ALAMEDA, Calif., Nov. 5, 2024…

Penumbra Receives CE Mark for Computer Assisted Vacuum Thrombectomy Technologies – Lightning Flash™ 2.0 and Lightning Bolt™ 7 – in Europe

Latest computer assisted vacuum thrombectomy (CAVT) technologies combine superior catheter design with the latest dual clot detection computer algorithms designed to restore blood flow quickly Lightning Flash™ 2.0 will be the most advanced thrombectomy system on the European market to address venous and pulmonary thrombus Lightning Bolt™ 7 is designed […]

Penumbra, Inc. Reports Second Quarter 2023 Financial Results

ALAMEDA, Calif., Aug. 1, 2023 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the second quarter ended June 30, 2023. Revenue of $261.5 million in the second quarter of 2023, an increase of 25.5% as reported and in constant currency1 compared to the second quarter of […]

Penumbra Expands Computer-Aided Thrombectomy Offerings with Lightning Bolt 7 Technology Designed to Rapidly Remove Blood Clots with Modulated Aspiration

Lightning Bolt™ 7 is the most advanced arterial thrombectomy system on the market Latest technology combines modulated aspiration with superior catheter design to maximize blood clot removal in a single session ALAMEDA, Calif., June 1, 2023 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, announced the U.S. Food […]

Penumbra, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results

ALAMEDA, Calif., Feb. 23, 2023 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the fourth quarter and full year ended December 31, 2022. Financial Highlights: Revenue of $221.2 million for the fourth quarter of 2022, an increase of 8.4% compared to revenue of $204.0 million for the fourth quarter […]